Innovation1 Biotech

Innovation1 Biotech is a U.S.-based public biotech/pharma company focused on developing science-based health products and, historically, synthetic analogs of botanical Schedule 1 molecules for unmet medical needs. Company materials describe a proprietary Quantum Core Technology (QCT™) platform used to analyze botanical compounds and design targeted formulations. Earlier disclosures highlighted pipeline ambitions in neurologic, psychiatric, dermatologic, and viral conditions, including a reported Phase 2 long-COVID program called NLC001. More recent SEC filings indicate the company currently has no operations and is evaluating strategic alternatives, including the possible acquisition of a new business. As a result, the business appears to be an active public shell or near-shell company rather than an operating clinical-stage biotech at present.